Monitor the ASCP presentation on May 26 for top-line Phase 3 data results. Positive data could be a significant catalyst for this $18M market cap biotech, while negative results would be bearish. No financial estimates are available from this filing.
Price Chart
Executive Summary
Lipocine announced that its Phase 3 clinical data for LPCN 1154 (oral brexanolone for postpartum depression) has been accepted for oral and poster presentation at the 2026 ASCP Annual Meeting (May 26-29). The presentation will highlight results from a placebo-controlled trial. No actual data or financial figures are disclosed; the event is a scientific conference presentation.
Key Facts
- Phase 3 data for LPCN 1154 accepted for oral and poster presentation at 2026 ASCP Annual Meeting
- Oral presentation on May 26, 2026 at 3:20 PM ET; poster on May 27, 2026
- No clinical data or financial results disclosed in the filing
- Presentation title: 'Novel Oral Rapid-Acting Neuroactive Steroid for Treatment of Postpartum Depression: A Placebo-Controlled Phase 3 Clinical Trial of LPCN 1154'
Financial Impact
Not specified
Risk Factors
- Phase 3 data may not meet primary endpoints
- Stock price could be volatile around the presentation date
- Company may need additional capital to advance pipeline
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-024365 |
| Exhibit: ex99-1.htm | 0001493152-26-024365 |
| Document: 0001493152-26-024365-index-headers.html | 0001493152-26-024365 |
| Document: 0001493152-26-024365-index.html | 0001493152-26-024365 |
| Document: 0001493152-26-024365.txt | 0001493152-26-024365 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | 8-K | $1.62 | awaiting T+60 | — | $1.46 (−9.88%) |
Oct 7, 2026 20d ago | 8-K | $2.20 | awaiting T+60 | — | $1.46 (−33.64%) |
Sep 16, 2026 5w ago | 8-K | $2.22 | awaiting T+60 | — | $1.46 (−34.23%) |
Sep 14, 2026 6w ago | 8-K | $2.22 | awaiting T+60 | — | $1.46 (−34.23%) |
Sep 11, 2026 6w ago | 8-K | $2.27 | awaiting T+60 | — | $1.46 (−35.68%) |
Sep 10, 2026 6w ago | 8-K | $2.25 | awaiting T+60 | — | $1.46 (−35.11%) |
Aug 4, 2026 12w ago | Press Release | $2.13 | awaiting T+60 | — | $1.46 (−31.46%) |
Aug 3, 2026 12w ago | 8-K | $2.11 | awaiting T+60 | — | $1.46 (−30.81%) |
Jun 4, 2026 20w ago | 8-K | $2.21 $2.17 | ▼ −1.81% | ▼ −3.69% | $1.46 (−33.94%) |
May 26, 2026 21w ago | 8-K | $2.28 $2.09 | ▼ −8.33% | ▼ −10.21% | $1.46 (−35.96%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers